Skip to main content
Erschienen in: Current Diabetes Reports 12/2014

01.12.2014 | Microvascular Complications—Neuropathy (D Ziegler, Section Editor)

The Charcot Foot as a Complication of Diabetic Neuropathy

verfasst von: Janice V. Mascarenhas, Edward B. Jude

Erschienen in: Current Diabetes Reports | Ausgabe 12/2014

Einloggen, um Zugang zu erhalten

Abstract

Diabetes mellitus is a leading global metabolic disorder accompanied by the overwhelming burden of its associated complications. Hyperglycaemia-induced endothelial damage or endothelial dysfunction serves as the primary instigator for the development of microvascular disease. Diabetic neuropathy represents the majority of microvascular sequelae and is the renowned perpetrator of a variety of foot complications, namely the Charcot foot (CF). CF is a debilitating medical emergency which is often mismanaged either due to a delayed diagnosis or lack of clinical expertise in the management of CF. Often, misdiagnosis during the acute stages of CF leads to irreversible and persistent joint destruction which may be refractory to medical or surgical treatment. Timely intervention with offloading measures is crucial during acute CF in ceasing active bone resorption. Current anti-resorptive agents may be considered as adjunctive therapy in combination with offloading. Novel agents are underway that will enable bone formation and suppress bone resorption.
Literatur
1.
Zurück zum Zitat Ziegler D, Rathmann W, Dickhaus T, et al. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care. 2008;31:464–9.PubMedCrossRef Ziegler D, Rathmann W, Dickhaus T, et al. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care. 2008;31:464–9.PubMedCrossRef
2.
Zurück zum Zitat Giacco F, Brownlee M. Pathogenesis of microvascular complications. Textbook of diabetes. 4th edition. Hoboken (NJ): Wiley-Blackwell; 2010. Giacco F, Brownlee M. Pathogenesis of microvascular complications. Textbook of diabetes. 4th edition. Hoboken (NJ): Wiley-Blackwell; 2010.
3.
Zurück zum Zitat Armstrong DG, Todd WF, Lavery LA, et al. The natural history of acute Charcot’s arthropathy in a diabetic foot specialty clinic. Diabet Med. 1997;14:357–63.PubMedCrossRef Armstrong DG, Todd WF, Lavery LA, et al. The natural history of acute Charcot’s arthropathy in a diabetic foot specialty clinic. Diabet Med. 1997;14:357–63.PubMedCrossRef
4.
Zurück zum Zitat Sanders LJ, Frykberg RG. Charcot neuroarthropathy of the foot. Levin and O’Neal’s the diabetic foot. 6th edition. St Louis (MO): Mosby; 2001; p. 439–65. Sanders LJ, Frykberg RG. Charcot neuroarthropathy of the foot. Levin and O’Neal’s the diabetic foot. 6th edition. St Louis (MO): Mosby; 2001; p. 439–65.
5.
Zurück zum Zitat Trepman E, Nihal A, Pinzur MS. Current topics review: Charcot neuroarthropathy of the foot and ankle. Foot Ankle Int. 2005;26:46–63.PubMed Trepman E, Nihal A, Pinzur MS. Current topics review: Charcot neuroarthropathy of the foot and ankle. Foot Ankle Int. 2005;26:46–63.PubMed
6.
Zurück zum Zitat Pinzur MS. Current concepts review: Charcot arthropathy of the foot and ankle. Foot Ankle Int. 2007;28:952–9.PubMedCrossRef Pinzur MS. Current concepts review: Charcot arthropathy of the foot and ankle. Foot Ankle Int. 2007;28:952–9.PubMedCrossRef
7.
Zurück zum Zitat Chantelau E, Onvlee GJ. Charcot foot in diabetes: farewell to the neurotrophic theory. Horm Metab Res. 2006;38:361–7.PubMedCrossRef Chantelau E, Onvlee GJ. Charcot foot in diabetes: farewell to the neurotrophic theory. Horm Metab Res. 2006;38:361–7.PubMedCrossRef
8.
Zurück zum Zitat Eckel RH, Wassef M, Chait A, et al. Prevention conference VI: diabetes and cardiovascular disease: writing group II: pathogenesis of atherosclerosis in diabetes. Circulation. 2002;105:e138–43.PubMedCrossRef Eckel RH, Wassef M, Chait A, et al. Prevention conference VI: diabetes and cardiovascular disease: writing group II: pathogenesis of atherosclerosis in diabetes. Circulation. 2002;105:e138–43.PubMedCrossRef
9.
Zurück zum Zitat Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813–20.PubMedCrossRef Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813–20.PubMedCrossRef
10.
Zurück zum Zitat Kumar P, Rao GN, Pal BB, et al. Hyperglycemia-induced oxidative stress induces apoptosis by inhibiting PI3-kinase/Akt and ERK1/2 MAPK mediated signaling pathway causing downregulation of 8-oxoG-DNA glycosylase levels in glial cells. Int J Biochem Cell Biol. 2014;53C:302–19.CrossRef Kumar P, Rao GN, Pal BB, et al. Hyperglycemia-induced oxidative stress induces apoptosis by inhibiting PI3-kinase/Akt and ERK1/2 MAPK mediated signaling pathway causing downregulation of 8-oxoG-DNA glycosylase levels in glial cells. Int J Biochem Cell Biol. 2014;53C:302–19.CrossRef
11.
Zurück zum Zitat Boulton AJ, Armstrong DG, Albert SF, et al. Comprehensive foot examination and risk assessment. A report of the Task Force of the Foot Care Interest Group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists. Phys Ther. 2008;88(11):1436–43.PubMed Boulton AJ, Armstrong DG, Albert SF, et al. Comprehensive foot examination and risk assessment. A report of the Task Force of the Foot Care Interest Group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists. Phys Ther. 2008;88(11):1436–43.PubMed
12.
Zurück zum Zitat Ziegler D. Diabetic peripheral neuropathy. Textbook of diabetes. 4th edition. Hoboken (NJ): Wiley-Blackwell; 2010. Ziegler D. Diabetic peripheral neuropathy. Textbook of diabetes. 4th edition. Hoboken (NJ): Wiley-Blackwell; 2010.
13.
Zurück zum Zitat Sugimoto K, Yasujima M, Yagihashi S. Role of advanced glycation end products in diabetic neuropathy. Curr Pharm Des. 2008;14:953–61.PubMedCrossRef Sugimoto K, Yasujima M, Yagihashi S. Role of advanced glycation end products in diabetic neuropathy. Curr Pharm Des. 2008;14:953–61.PubMedCrossRef
14.
Zurück zum Zitat Vlassara H, Brownlee M, Cerami A. Nonenzymatic glycosylation of peripheral nerve protein in diabetes mellitus. Proc Natl Acad Sci U S A. 1981;78:5190–2.PubMedCentralPubMedCrossRef Vlassara H, Brownlee M, Cerami A. Nonenzymatic glycosylation of peripheral nerve protein in diabetes mellitus. Proc Natl Acad Sci U S A. 1981;78:5190–2.PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Edmonds ME, Morrison N, Laws JW, et al. Medial arterial calcification and diabetic neuropathy. Br Med J (Clin Res Ed). 1982;284:928–30.CrossRef Edmonds ME, Morrison N, Laws JW, et al. Medial arterial calcification and diabetic neuropathy. Br Med J (Clin Res Ed). 1982;284:928–30.CrossRef
16.•
Zurück zum Zitat Shu A, Yin MT, Stein E, et al. Bone structure and turnover in type 2 diabetes mellitus. Osteoporos Int. 2012;23(2):635–41. This study illustrates that patients with type 2 DM have poor bone quality despite a higher BMD.PubMedCentralPubMedCrossRef Shu A, Yin MT, Stein E, et al. Bone structure and turnover in type 2 diabetes mellitus. Osteoporos Int. 2012;23(2):635–41. This study illustrates that patients with type 2 DM have poor bone quality despite a higher BMD.PubMedCentralPubMedCrossRef
17.
Zurück zum Zitat Wimalawansa SJ. Rationale for using nitric oxide donor therapy for prevention of bone loss and treatment of osteoporosis in humans. Ann NY Acad Sci. 2007;1117:283–97.PubMedCrossRef Wimalawansa SJ. Rationale for using nitric oxide donor therapy for prevention of bone loss and treatment of osteoporosis in humans. Ann NY Acad Sci. 2007;1117:283–97.PubMedCrossRef
18.
Zurück zum Zitat Grant WP, Sullivan R, Sonenshine DE, et al. Electron microscopic investigation of the effects of diabetes mellitus on the Achilles tendon. J Foot Ankle Surg. 1997;36:272–8. Discussion: 330.PubMedCrossRef Grant WP, Sullivan R, Sonenshine DE, et al. Electron microscopic investigation of the effects of diabetes mellitus on the Achilles tendon. J Foot Ankle Surg. 1997;36:272–8. Discussion: 330.PubMedCrossRef
19.
Zurück zum Zitat Joseph AL, Ernesto C, Lawrence GR. Metabolic bone disease. Williams textbook of endocrinology. 12th edition. Philadelphia: Elsevier; 2011; p. 1310. Joseph AL, Ernesto C, Lawrence GR. Metabolic bone disease. Williams textbook of endocrinology. 12th edition. Philadelphia: Elsevier; 2011; p. 1310.
20.
Zurück zum Zitat Petrova NL, Shanahan CM. Neuropathy and the vascular-bone axis in diabetes: lessons from Charcot osteoarthropathy. Osteoporos Int. 2014;25:1197–207.PubMedCrossRef Petrova NL, Shanahan CM. Neuropathy and the vascular-bone axis in diabetes: lessons from Charcot osteoarthropathy. Osteoporos Int. 2014;25:1197–207.PubMedCrossRef
21.
Zurück zum Zitat Reiber GE, Vileikyte L, Boyko EJ, et al. Causal pathways for incident lower extremity ulcers in patients with diabetes from two settings. Diabetes Care. 1999;22:157–62.PubMedCrossRef Reiber GE, Vileikyte L, Boyko EJ, et al. Causal pathways for incident lower extremity ulcers in patients with diabetes from two settings. Diabetes Care. 1999;22:157–62.PubMedCrossRef
22.
Zurück zum Zitat Thomas CC, Eichenholtz SN. Charcot joints. Springfield (IL):1966. Thomas CC, Eichenholtz SN. Charcot joints. Springfield (IL):1966.
23.
Zurück zum Zitat Johnson JE. Operative treatment of neuropathic arthropathy of the foot and ankle. J Bone Joint Surg Am. 1998;80:1700–9. Johnson JE. Operative treatment of neuropathic arthropathy of the foot and ankle. J Bone Joint Surg Am. 1998;80:1700–9.
24.
Zurück zum Zitat Schon LC, Easley ME, Weinfeld SB. Charcot neuroarthropathy of the foot and ankle. Clin Orthop Relat Res. 1998;349:116–31.PubMedCrossRef Schon LC, Easley ME, Weinfeld SB. Charcot neuroarthropathy of the foot and ankle. Clin Orthop Relat Res. 1998;349:116–31.PubMedCrossRef
25.
Zurück zum Zitat Schlossbauer T, Mioc T, Sommerey S, Kessler SB, Reiser MF, Pfeifer KJ. Magnetic resonance imaging in early stage Charcot arthropathy—correlation of imaging findings and clinical symptoms. Eur J Med Res. 2008;13:409–14.PubMed Schlossbauer T, Mioc T, Sommerey S, Kessler SB, Reiser MF, Pfeifer KJ. Magnetic resonance imaging in early stage Charcot arthropathy—correlation of imaging findings and clinical symptoms. Eur J Med Res. 2008;13:409–14.PubMed
26.
Zurück zum Zitat Foltz KD, Fallat LM, Schwartz S. Usefulness of a brief assessment battery for early detection of Charcot foot deformity in patients with diabetes. J Foot Ankle Surg. 2004;43(2):87–92.PubMedCrossRef Foltz KD, Fallat LM, Schwartz S. Usefulness of a brief assessment battery for early detection of Charcot foot deformity in patients with diabetes. J Foot Ankle Surg. 2004;43(2):87–92.PubMedCrossRef
27.
Zurück zum Zitat Rogers LC, Bevilacqua NJ. Imaging of the Charcot foot. Clin Podiatr Med Surg. 2008;25:263–74.PubMedCrossRef Rogers LC, Bevilacqua NJ. Imaging of the Charcot foot. Clin Podiatr Med Surg. 2008;25:263–74.PubMedCrossRef
28.•
Zurück zum Zitat Bramham R, Wraight P, May K. Management of Charcot neuroarthropathy. Diabet Foot J. 2011;14(4):163–70. This is a review article which emphasizes on timely intervention in the management of both acute and chronic CF. Bramham R, Wraight P, May K. Management of Charcot neuroarthropathy. Diabet Foot J. 2011;14(4):163–70. This is a review article which emphasizes on timely intervention in the management of both acute and chronic CF.
29.
Zurück zum Zitat Sanders LJ, Mrdjenovich D. Anatomical patterns of bone and joint destruction in neuropathic diabetics. Diabetes. 1991;40:529A. Sanders LJ, Mrdjenovich D. Anatomical patterns of bone and joint destruction in neuropathic diabetics. Diabetes. 1991;40:529A.
30.
Zurück zum Zitat Sanders LJ, Frykberg RG. Diabetic neuropathic osteoarthropathy: Charcot foot. In: Levin ME, O’Neal LW, Bowker JH, editors. The high risk foot in diabetes mellitus. New York: Churchill Livingstone; 1991. p. 297–338. Sanders LJ, Frykberg RG. Diabetic neuropathic osteoarthropathy: Charcot foot. In: Levin ME, O’Neal LW, Bowker JH, editors. The high risk foot in diabetes mellitus. New York: Churchill Livingstone; 1991. p. 297–338.
31.••
Zurück zum Zitat Rogers LC, Frykberg RG, Armstrong DG, et al. The Charcot foot in diabetes. Diabetes Care. 2011;34:2123–9. This article is a recent consensus statement by the ADA which provides treating clinicians with an overview of the pathophysiology of CF. It also highlights the use of appropriate diagnostic techniques and therapeutic interventions to be applied according to various stages of CF.PubMedCentralPubMedCrossRef Rogers LC, Frykberg RG, Armstrong DG, et al. The Charcot foot in diabetes. Diabetes Care. 2011;34:2123–9. This article is a recent consensus statement by the ADA which provides treating clinicians with an overview of the pathophysiology of CF. It also highlights the use of appropriate diagnostic techniques and therapeutic interventions to be applied according to various stages of CF.PubMedCentralPubMedCrossRef
32.
Zurück zum Zitat Kimmerle R, Chantelau E. Weight-bearing intensity produces Charcot deformity in injured neuropathic feet in diabetes. Exp Clin Endocrinol Diabetes. 2007;115:360–4.PubMedCrossRef Kimmerle R, Chantelau E. Weight-bearing intensity produces Charcot deformity in injured neuropathic feet in diabetes. Exp Clin Endocrinol Diabetes. 2007;115:360–4.PubMedCrossRef
33.
Zurück zum Zitat Armstrong DG, Lavery LA. Monitoring healing of acute Charcot’s arthropathy with infrared dermal thermometry. J Rehabil Res Dev. 1997;34:317–21.PubMed Armstrong DG, Lavery LA. Monitoring healing of acute Charcot’s arthropathy with infrared dermal thermometry. J Rehabil Res Dev. 1997;34:317–21.PubMed
34.
Zurück zum Zitat Giurini JM. Applications and use of in-shoe orthoses in the conservative management of Charcot foot deformity. Clin Podiatr Med Surg. 1994;11:271–8.PubMed Giurini JM. Applications and use of in-shoe orthoses in the conservative management of Charcot foot deformity. Clin Podiatr Med Surg. 1994;11:271–8.PubMed
35.
Zurück zum Zitat Frykberg RG, Zgonis T, Armstrong DG, et al. Diabetic foot disorders. A clinical practice guideline (2006 revision). J Foot Ankle Surg. 2006;45:1–66.CrossRef Frykberg RG, Zgonis T, Armstrong DG, et al. Diabetic foot disorders. A clinical practice guideline (2006 revision). J Foot Ankle Surg. 2006;45:1–66.CrossRef
36.
Zurück zum Zitat Armstrong DG, Nguyen HC, Lavery LA, van Schie CH, Boulton AJ, Harkless LB. Off-loading the diabetic foot wound: a randomized clinical trial. Diabetes Care. 2001;24:1019–22.PubMedCrossRef Armstrong DG, Nguyen HC, Lavery LA, van Schie CH, Boulton AJ, Harkless LB. Off-loading the diabetic foot wound: a randomized clinical trial. Diabetes Care. 2001;24:1019–22.PubMedCrossRef
37.
Zurück zum Zitat Russell RG, Watts NB, Ebetino FH, et al. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008;19:733–59.PubMedCrossRef Russell RG, Watts NB, Ebetino FH, et al. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008;19:733–59.PubMedCrossRef
38.
Zurück zum Zitat Lehenkari PP, Kellinsalmi M, Napankangas JP, et al. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol. 2002;61:1255–62.PubMedCrossRef Lehenkari PP, Kellinsalmi M, Napankangas JP, et al. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol. 2002;61:1255–62.PubMedCrossRef
39.
41.
Zurück zum Zitat Selby PL, Young MJ, Boulton AJ. Bisphosphonates: a new treatment for diabetic Charcot neuroarthropathy? Diabet Med. 1994;11:28–31.PubMedCrossRef Selby PL, Young MJ, Boulton AJ. Bisphosphonates: a new treatment for diabetic Charcot neuroarthropathy? Diabet Med. 1994;11:28–31.PubMedCrossRef
42.
Zurück zum Zitat Jude EB, Selby PL, Burgess J, et al. Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial. Diabetologia. 2001;44:2032–7.PubMedCrossRef Jude EB, Selby PL, Burgess J, et al. Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial. Diabetologia. 2001;44:2032–7.PubMedCrossRef
43.
Zurück zum Zitat Pitocco D, Ruotolo V, Caputo S, et al. Six-month treatment with alendronate in acute Charcot neuroarthropathy: a randomized controlled trial. Diabetes Care. 2005;28:1214–5.PubMedCrossRef Pitocco D, Ruotolo V, Caputo S, et al. Six-month treatment with alendronate in acute Charcot neuroarthropathy: a randomized controlled trial. Diabetes Care. 2005;28:1214–5.PubMedCrossRef
44.
Zurück zum Zitat Zaidi M, Inzerillo AM, Moonga BS, et al. Forty years of calcitonin—where are we now? A tribute to the work of Iain Macintyre, FRS. Bone. 2002;30:655–63.PubMedCrossRef Zaidi M, Inzerillo AM, Moonga BS, et al. Forty years of calcitonin—where are we now? A tribute to the work of Iain Macintyre, FRS. Bone. 2002;30:655–63.PubMedCrossRef
45.
Zurück zum Zitat Kapurniato A, Taylor JW. Structural and conformational requirements for human calcitonin activity. Design, synthesis and study of lactam bridge analogs. J Med Chem. 1995;38:836–47.CrossRef Kapurniato A, Taylor JW. Structural and conformational requirements for human calcitonin activity. Design, synthesis and study of lactam bridge analogs. J Med Chem. 1995;38:836–47.CrossRef
46.
Zurück zum Zitat Bem R, Jirkovska A, Fejfarova V, et al. Intranasal calcitonin in the treatment of acute Charcot neuroosteoarthropathy: a randomized controlled trial. Diabetes Care. 2006;29:1392–4.PubMedCrossRef Bem R, Jirkovska A, Fejfarova V, et al. Intranasal calcitonin in the treatment of acute Charcot neuroosteoarthropathy: a randomized controlled trial. Diabetes Care. 2006;29:1392–4.PubMedCrossRef
47.
Zurück zum Zitat Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009;24:153–61.PubMedCrossRef Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009;24:153–61.PubMedCrossRef
48.
Zurück zum Zitat Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004;50:1400–11.PubMedCrossRef Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004;50:1400–11.PubMedCrossRef
49.
Zurück zum Zitat van der Heijde D, Klareskog L, Rodriguez-Valverde V, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum. 2006;54:1063–74.PubMedCrossRef van der Heijde D, Klareskog L, Rodriguez-Valverde V, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum. 2006;54:1063–74.PubMedCrossRef
50.
Zurück zum Zitat Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000;343:1594–602.PubMedCrossRef Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000;343:1594–602.PubMedCrossRef
52.
Zurück zum Zitat Cohen SB, Moreland LW, Cush JJ, et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis. 2004;63:1062–8.PubMedCentralPubMedCrossRef Cohen SB, Moreland LW, Cush JJ, et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis. 2004;63:1062–8.PubMedCentralPubMedCrossRef
Metadaten
Titel
The Charcot Foot as a Complication of Diabetic Neuropathy
verfasst von
Janice V. Mascarenhas
Edward B. Jude
Publikationsdatum
01.12.2014
Verlag
Springer US
Erschienen in
Current Diabetes Reports / Ausgabe 12/2014
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-014-0561-6

Weitere Artikel der Ausgabe 12/2014

Current Diabetes Reports 12/2014 Zur Ausgabe

Pathogenesis of Type 1 Diabetes (A Pugliese, Section Editor)

Extracellular Matrix Components in the Pathogenesis of Type 1 Diabetes

Pathogenesis of Type 1 Diabetes (A Pugliese, Section Editor)

Interleukin 2 in the Pathogenesis and Therapy of Type 1 Diabetes

Pathogenesis of Type 2 Diabetes and Insulin Resistance (RM Watanabe, Section Editor)

Glucagon and Type 2 Diabetes: the Return of the Alpha Cell

Lifestyle Management to Reduce Diabetes/Cardiovascular Risk (EM Venditti, Section Editor)

Lifestyle Interventions to Reduce Diabetes and Cardiovascular Disease Risk Among Children

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Hereditäres Angioödem: Tablette könnte Akuttherapie erleichtern

05.06.2024 Hereditäres Angioödem Nachrichten

Medikamente zur Bedarfstherapie bei hereditärem Angioödem sind bisher nur als Injektionen und Infusionen verfügbar. Der Arzneistoff Sebetralstat kann oral verabreicht werden und liefert vielversprechende Daten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.